Erlotinib may confer an economic advantage for payers over docetaxel and pemetrexed for second-line treatment of lung cancer because of lower costs.
Henry J. Henk, PhD
Advertisement
Articles by Henry J. Henk, PhD
Advertisement
Latest Updated Articles
- Costs Associated With Second-Line Therapies for Lung Cancer
February 1st 2011
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves First-in-Class Daraxonrasib for Metastatic Pancreatic Cancer
2
What Pharmacists Should Know About Novo Nordisk-Eli Lilly GLP-1 Ad Suit
3
FDA Approves Dolutegravir for HIV Treatment in Newborns
4
FDA Clears First Continuous Glucose-Ketone Monitor
5